Latest:
Meet our Steering Committee
Second Closed Scientific Expert Meeting
of the Editorial Board
Keynote – Pancreatitis: Pathophysiology
Pancreatitis pathophysiology is a dynamic process of sudden acute inflammation triggered by trypsin activation which can lead to cytokine storm and systemic inflammatory response syndrome, capillary leak system and multi-organ failure over 48 hours. Prof David Whitcomb discusses the importance of effective evaluation and prompt treatment.
Watch presentation >
Keynote – TGRLs and remnants: How do we assess their risk?
In his state-of-the-art presentation, Prof Henry Ginsberg discusses the role of TG-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease, with a focus on how and why remnants accumulate in some individuals and how levels of remnant particles and their cholesterol can be assessed.
Watch presentation >
Clinical trials of innovative therapeutics
New insights into the biology of triglyceride metabolism underpin the development of novel therapies for managing hypertriglyceridaemia to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and, for severely elevated levels, pancreatitis.
In the last decade epidemiology and genetic studies – in particular, Mendelian randomisation studies – have moved the field forward and we are on the cusp of a new era in managing elevated triglycerides.
Major outcomes studies with these new therapies are fundamental to answering the much-debated question:
Does lowering elevated triglycerides reduce residual cardiovascular risk?
Expert Commentary
ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
Dr Michael Miller, Professor of Cardiovascular Medicine at the University of Maryland, Baltimore, USA, and co-author of the recent American College of Cardiology Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent Hypertriglyceridaemia discusses the background to the new guidance and the recommendation to stratify patients for treatment according to their residual LDL-cholesterol level.
About Triglyceride Forum
The Triglyceride Forum is a unique, independent, expert-led global initiative to address the rapidly evolving field of triglycerides and triglyceride-rich lipoproteins in cardiovascular disease and pancreatitis. This Forum will provide clinicians and researchers with international, open access, peer-reviewed resources at an important time when new and innovative molecules are at advanced stages of development… Read more >>
Why join?
Professors Ginsberg and Chapman explain the fundamental scientific and clinical research that has turned the spotlight on triglyceride-rich lipoproteins and their remnants as important players in the development of atherosclerotic CVD and pancreatitis and as targets for novel therapies for both these serious diseases.
FREE MEMBERSHIP
Join the Triglyceride Forum for open access to independent, evidence based knowledge and high quality educational programmes
View invitation from Henry Ginsberg
Join the Triglyceride Forum to share new data and exchange opinions with clinicians and researchers around the world
View invitation from John Chapman
MAKING THE CONNECTION: TRIGLYCERIDES, RESIDUAL CV RISK AND PANCREATITIS
This unique, downloadable slide deck developed specially for Triglyceride Forum is a state-of-the-art guide to triglycerides and their association with residual cardiovascular risk and pancreatitis.
Why triglycerides now?
From the editors
Educational partners and supporters
